经济观察网特宝生物近期公告显示，公司拟发行可转换公司债券募集资金总额不超过15.33亿元，用于 新药研发等项目。同时，公司2025年业绩快报显示营业收入36.96亿元，同比增长31.18%，归母净利润 10.38亿元，同比增长25.39%。 定增股票 业绩经营情况 公司于2026年2月10日晚间披露了2025年业绩快报，显示营业收入36.96亿元，同比增长31.18%，归母净 利润10.38亿元，同比增长25.39%。业绩增长主要受重点产品派格宾销售收入稳定增长及新产品益佩生 上市推动。 以上内容基于公开资料整理，不构成投资建议。 特宝生物于2026年1月26日晚间公告，拟发行可转换公司债券募集资金总额不超过15.33亿元，用于新药 研发项目、生物技术创新融合中心建设项目及创新药物生产改扩项目。这一计划旨在加码主业，提升研 发能力和产能。 ...

Group 1 - The core viewpoint of the announcement is that Foxit Software will focus on AI-driven product innovation and deepen its dual transformation of subscriptions and channels, while also planning to expand its business scale through external mergers and acquisitions [1] - The profit distribution plan for 2024 includes a proposal to distribute 3 yuan for every 10 shares [1] Group 2 - In the recent stock performance, Foxit Software's stock price showed a volatile rebound trend, stabilizing and recovering on February 12, 2026 [2] - On February 11, there was a net outflow of main funds, while speculative funds showed a net inflow, indicating short-term capital divergence [2] Group 3 - According to a report from Shanghai Securities, the ongoing AI transformation is deepening, with overseas giants upgrading their large model capabilities and increasing capital expenditures, which may indirectly benefit AI application companies [3] - As a provider of PDF solutions, Foxit Software's AI intelligent document processing business may benefit from these industry trends [3]

经济观察网 中天火箭（003009）（003009）近7天股价呈现震荡走势。截至2026年2月13日收盘，股价 报67.22元，当日上涨0.95%，振幅3.51%，成交额2.25亿元；主力资金净流出1403.25万元，散户资金净 流入1403.25万元。近5日累计下跌1.88%，区间最高价为70.99元（2月10日），最低价为66.14元（2月13 日）。技术面显示，当前股价处于布林带下轨附近，20日均线压力位75.68元，支撑位64.98元；MACD 指标偏弱，KDJ指标处于超卖区域。同期国防军工板块上涨0.69%，但航天装备Ⅱ板块下跌0.80%，公司 股价表现弱于行业平均水平。 近期事件 近期航天领域热点事件可能对板块情绪产生间接影响。2026年2月11日，长征十号运载火箭成功完成载 人飞船逃逸试验，标志着我国载人月球探测工程取得阶段性突破，或提振航天装备行业关注度。中天火 箭于2月10日推出首款航天AI文创产品"龙小曦"，融合AI交互技术，旨在通过文化传播提升品牌影响 力，但该产品属于创新尝试，对短期业绩影响有限。 机构观点 机构对中天火箭近期评级偏中性。根据2026年2月13日数据，机构综合目标价为7 ...

Company Developments - The company is advancing a significant asset restructuring by acquiring 90% of Shudun Information Technology Co., Ltd. through a combination of issuing shares and cash, with the transaction suspended from November 24, 2025, and expected to resume on December 8, 2025. Due diligence, auditing, and evaluation are ongoing as of February 6, 2026, and the transaction is subject to board, shareholder, Shanghai Stock Exchange, and China Securities Regulatory Commission approvals, indicating uncertainty in successful implementation [2] - In January 2026, a shareholder, Shanghai Pugang Enterprise Management Center (Limited Partnership), reduced its stake in the company through a block trade, resulting in a combined holding with its concert party, Li Jin, dropping to 5% [3] Governance Structure - In December 2025, the company approved a resolution to abolish the supervisory board and revised its articles of association and related internal management systems to comply with the new Company Law. The governance structure will now have the board's audit committee exercising the powers of the supervisory board [4] Financial Performance - The company continues to face operational challenges, with a forecasted net loss of between 110 million to 165 million yuan for the full year of 2025, excluding non-recurring gains and losses. The Q3 2025 report indicated a net profit attributable to shareholders of -67.24 million yuan, with revenue declining by 30.72% year-on-year [5]

Group 1 - The stock price of Chengda Pharmaceutical (301201) experienced significant fluctuations, with a single-day increase of 3.17% on February 12, 2026, and a total market capitalization of 6.351 billion yuan [1] - The market focus is on sectors such as cell immunotherapy, hepatitis concepts, and CRO concepts, which are driving investor interest [1] - On February 13, the stock continued its upward trend, closing at 41.67 yuan, reflecting a 1.51% increase from the previous day [1] Group 2 - Over the past 7 trading days (February 6 to February 13, 2026), the stock price rose from 38.05 yuan to 41.67 yuan, marking a cumulative increase of 9.51% with a volatility of 11.30% [2] - On February 12, there was a net inflow of 17.2629 million yuan from main funds, indicating a continuous increase in positions for two consecutive days [2] - As of February 11, the balance of margin financing and securities lending was 305 million yuan, showing a decrease of 0.42% from the previous day [2]

经济观察网华民股份（300345）近期股价调整主要与业绩持续亏损、行业基本面承压、资金面与市场情 绪影响及技术面调整压力等因素相关。 业绩经营情况 尽管2025年光伏新增装机量保持增长，但行业仍面临阶段性供需失衡，主要产品价格处于相对低位。虽 然行业自律限产推动价格有所回暖，但整体盈利修复仍需时间。2025年三季报显示，公司毛利率仅为 4.03%，资产负债率高达87.11%，财务压力较大。 资金面与技术面 从资金流向看，2025年7月至11月期间，主力资金曾出现阶段性净流出，叠加控股股东协议转让股份的 消息，加剧了股价波动。截至2025年三季度末，公司经营活动现金流净额为-9622.91万元，现金流紧张 状况尚未根本缓解。从近期走势看，股价在2026年2月9日触及8.74元高点后回落，短期获利盘了结压力 显现。2月13日收盘价7.35元，跌破5日均线，技术面呈现调整态势。 以上内容基于公开资料整理，不构成投资建议。 根据公司业绩预告，预计2025年全年归母净利润亏损1.5亿元至1.9亿元。虽然亏损额较2024年同期有所 收窄，但公司自2017年起扣非净利润已连续多年为负，持续亏损对市场信心造成压力。 行业政策 ...

经济观察网康尼机电（603111）近期有以下值得关注的事件：公司计划未来三年每股现金分红年增长比 例不低于10%，该政策基于公司"提质增效重回报"行动方案，旨在提升股东回报。公司管理层表示对未 来能与产业形成优势互补的合作机遇保持开放态度，并将进行必要评估与研究，但暂无具体资本合作计 划。 以上内容基于公开资料整理，不构成投资建议。 ...

创新药审批加速等政策持续优化，生物技术板块情绪可能受到提振。公司作为双特异性抗体研发企业， 其技术平台和管线价值在行业创新周期中可能被重估。 公司注射用重组抗EpCAM/CD3双特异性抗体M701获得美国FDA的临床试验申请批准，用于治疗恶性胸 腔积液。该药物在中国开展的II期临床试验数据显示其能显著延长患者无穿刺生存时间，国际化进展可 能成为股价催化因素。此外，其用于A型血友病治疗的舒友立乐生物类似药Y225的临床试验申请获中国 国家药监局批准，进一步拓展了管线布局。 公司结构与治理 经济观察网友芝友生物-B近期核心产品研发取得进展，公司治理与财务表现出现改善信号，同时市场与 政策环境存在利好。 2025年上半年财报显示净亏损同比收窄，主要得益于与正大天晴的许可合作带来的研发服务收入增长。 后续商业化合作进展及现金流改善情况值得跟踪。 产品研发进展 行业政策与环境 职工代表监事王涛博士因个人职业发展原因辞职，由转化医学部总监石剑博士接任。此类人事变动需关 注后续公司治理稳定性。 业绩经营情况 以上内容基于公开资料整理，不构成投资建议。 ...

经济观察网立新能源（001258）发布2025年业绩预告，预计净利润同比增长89.31%至119.20%，主要得 益于新增风电及储能项目投产，以及联营企业项目贡献投资收益。公司向特定对象发行股票(定增)事项 目前处于已问询阶段，募资额及部分项目投资额有所调减。 公司项目推进 新增风电及储能项目已于2025年投产，联营企业项目持续贡献收益。这些项目的后续运营情况可能影响 公司业绩。 业绩经营情况 以上内容基于公开资料整理，不构成投资建议。 公司于2026年1月29日发布2025年度业绩预告，预计归属于上市公司股东的净利润为9,500万元至11,000 万元，同比增长89.31%至119.20%。业绩增长主要因新增风电及独立储能项目投产带来上网电量增加， 以及联营企业"疆电外送"三通道发电项目投运贡献投资收益。2025年年度报告尚未正式披露。 定增股票 公司定增事项处于已问询阶段。2025年，公司调减了募资额，其中补充流动资金部分下调1.5亿元，并 调减了"三塘湖20万千瓦/80万千瓦时储能+80万千瓦风电项目"的投资额。定增最终结果有待监管审核。 ...

Group 1 - The chemical industry is experiencing favorable policies, particularly in the pesticide sector, with 94 pesticide varieties, including glyphosate, set to enjoy VAT export tax rebates starting April 1, 2026, which is expected to lower costs for pesticide companies and boost export demand [1] - As a listed company in the agrochemical sector, Bluestar Bio-chemical (002513) may benefit indirectly from the overall improvement in industry sentiment due to these policies [1] - The chemical sector is showing active performance, with price increases in disperse dyes driving related stocks up, although Bluestar Bio-chemical's main business focuses on pesticides, necessitating attention to the policy's specific impact on its operations [1] Group 2 - In the past seven trading days, Bluestar Bio-chemical's stock price has shown a downward trend, closing at 7.25 yuan on February 13, down 6.45% from a high of 7.75 yuan on February 9, with a price fluctuation of 7.84% during this period [2] - On February 13, there was a net outflow of 4.2618 million yuan from major investors, while retail investors showed a net inflow [2] - Technically, the stock is currently near the middle band of the 20-day Bollinger Bands, with a short-term resistance level at 7.78 yuan and a support level at 6.83 yuan, while the MACD indicator suggests a cautious market sentiment [2]